

## Appendix 1. Search strategies.

| Cognitive enhancer | MEDLINE (Ovid)                                                                                                                                                                                                                                                                                                                                                                                                                                  | EMBASE (Ovid)                                                                                                                                                                                                                                                                                                                                                                                                                                                   | CENTRAL (Cochrane)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Galantamine</b> | 1. exp Galantamine/<br>2. Galantamin*<br>3. Galanthamin*<br>4. Nivalin*<br>5. Razadyn*<br>6. Reminyl*<br>7. Lycopremin*<br>8. Jilkon.ti,ab.<br>9. (0D3Q044KCA or "357 70 0" or 609 175 3).rn.<br>10. or/1-9<br>11. exp clinical trial/<br>12. exp randomized controlled trials/<br>13. exp double-blind method/<br>14. exp single-blind method/<br>15. exp cross-over studies/<br>16. randomized controlled trial.pt.<br>17. clinical trial.pt. | 1. exp Galantamine/<br>2. Galantamin*<br>3. Galanthamin*<br>4. Nivalin*<br>5. Razadyn*<br>6. Reminyl*<br>7. Lycopremin*<br>8. Jilkon.ti,ab.<br>9. (0D3Q044KCA or "357 70 0" or 609 175 3).rn.<br>10. or/1-9<br>11. (clin\$ adj2 trial).mp.<br>12. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).mp.<br>13. (random\$ adj5 (assign\$ or allocat\$)).mp.<br>14. randomi\$.mp.<br>15. crossover.mp.<br>16. exp randomized-controlled-trial/ | 1. MeSH descriptor: [Schizophrenia] this term only<br>2. MeSH descriptor: [Paranoid Disorders] this term only<br>3. schizo* in Trials<br>4. hebephreni* in Trials<br>5. oligophreni* in Trials<br>6. psychotic* in Trials<br>7. psychosis in Trials<br>8. psychoses in Trials<br>9. chronic* in Trials<br>10. sever* in Trials<br>11. mental* in Trials<br>12. ill* in Trials<br>13. disorder* in Trials<br>14. (#9 or #10)<br>15. (#14 and #11)<br>16. (#12 or #13)<br>17. (#15 and #16) |

|                                                                               |                                                                                                               |                                                           |
|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| 18. controlled clinical trial.pt.                                             | 17. exp double-blind-procedure/                                                                               | 18. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #17) |
| 19. (clinic\$ adj2 trial).mp.                                                 | 18. exp crossover-procedure/                                                                                  | 19. tardiv* in Trials                                     |
| 20. (random\$ adj5 control\$ adj5 trial\$).mp.                                | 19. exp single-blind-procedure/                                                                               | 20. dyskine* in Trials                                    |
| 21. (crossover or cross-over).mp.                                             | 20. exp randomization/                                                                                        | 21. (#19 and #20)                                         |
| 22. ((singl\$ or double\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).mp. | 21. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20                                                  | 22. akathisi* in Trials                                   |
| 23. randomi\$.mp.                                                             | 22. (schizo\$ or psychotic\$ or psychosis or psychoses).mp.                                                   | 23. acathisi* in Trials                                   |
| 24. (random\$ adj5 (assign\$ or allocat\$ or assort\$ or reciev\$)).mp.       | 23. ((chronic\$ or severe\$ or persistent\$) adj (mental\$ or psychological\$) adj (disorder\$ or ill\$)).mp. | 24. neuroleptic* in Trials                                |
| 25. or/11-24                                                                  | 24. exp schizophrenia/                                                                                        | 25. malignant in Trials                                   |
| 26. exp SCHIZOPHRENIA/                                                        | 25. exp psychosis/                                                                                            | 26. syndrome in Trials                                    |
| 27. exp Paranoid Disorders/                                                   | 26. mental patient/                                                                                           | 27. (#25 and #26)                                         |
| 28. schizo\$.mp.                                                              | 27. (tardiv\$ adj dyskine\$).mp.                                                                              | 28. (#24 and #27)                                         |
| 29. hebephreni\$.mp.                                                          | 28. neuroleptic agent/                                                                                        | 29. movement in Trials                                    |
| 30. oligophreni\$.mp.                                                         |                                                                                                               | 30. disorder* in Trials                                   |
| 31. psychotic\$.mp.                                                           |                                                                                                               | 31. (#24 and #29 and #30)                                 |
| 32. psychosis.mp.                                                             |                                                                                                               | 32. parkinsoni* in Trials                                 |
|                                                                               |                                                                                                               | 33. neuroleptic-induc* in Trials                          |
|                                                                               |                                                                                                               | 34. parkinson's in Trials                                 |
|                                                                               |                                                                                                               | 35. disease in Trials                                     |

|                        |                         |                          |
|------------------------|-------------------------|--------------------------|
| 33. psychoses.mp.      | 29. (neuroleptic\$ and  | 36. disease:ti in Trials |
| 34. ((chronic\$ or     | (malignant adj2         | 37. (#34 and #36)        |
| sever\$) adj2 mental\$ | syndrome)).mp.          | 38. (#21 or #22 or       |
| adj2 (ill\$ or         | 30. tardive dyskinesia/ | #23 or #28 or #31 or     |
| disorder\$)).mp.       | 31. akathisia/          | #32 or #33)              |
| 35. exp dyskinesia,    | 32. exp neuroleptic     | 39. (#38 and not #37)    |
| drug-induced/          | malignant syndrome/     | 40. MeSH descriptor:     |
| 36. exp psychomotor    | 33. (neuroleptic\$ and  | [Dyskinesia, Drug-       |
| agitation/             | movement and            | Induced] this term       |
| 37. exp neuroleptic    | disorder\$).mp.         | only                     |
| malignant syndrome/    | 34. parkinsoni\$.mp.    | 41. MeSH descriptor:     |
| 38. exp "diagnosis,    | 35. parkinson's.mp.     | [Akathisia, Drug-        |
| dual (psychiatry)"/    | 36. 22 or 23 or 24 or   | Induced] explode all     |
| 39. (tardiv\$ adj      | 25 or 26 or 27 or 28 or | trees                    |
| dyskine\$).mp.         | 29 or 30 or 31 or 32 or | 42. MeSH descriptor:     |
| 40. akathisi\$.mp.     | 33 or 34 or 35          | [Neuroleptic             |
| 41. acathisi\$.mp.     | 37. 36 not              | Malignant Syndrome]      |
| 42. (neuroleptic\$ and | parkinson's.ti.         | this term only           |
| (malignant adj2        | 38. 21 and 37           | 43. (#39 or #40 or       |
| syndrome)).mp.         | 39. 10 and 38           | #41 or #42)              |
| 43. (neuroleptic\$ and |                         | 44. (#43 or #18)         |
| (movement and          |                         | 45. MeSH descriptor:     |
| disorder\$)).mp.       |                         | [Schizophrenia           |
| 44. parkinsoni\$.mp.   |                         | Spectrum and Other       |
| 45. neuroleptic-       |                         | Psychotic Disorders]     |
| induc\$.mp.            |                         | this term only           |
| 46. or/39-45           |                         | 46. (#45 or #44)         |

|                  |                                                                                                                                                                                              |                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                        |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | 47. 46 not (parkinson's<br>adj1 disease).ti.<br>48. or/26-38<br>49. 47 or 48<br>50. 25 and 49<br>51. 10 and 50                                                                               |                                                                                                                                                                                      | 47. MeSH descriptor:<br>[Galantamine]<br>explode all trees<br>48. Galantamin*<br>49. Galanthamin*<br>50. Nivalin*<br>51. Razadyn*<br>52. Reminyl*<br>53. Lycoremin*<br>54. Jilkon<br>55. 0D3Q044KCA<br>56. (#47 or #48 or<br>#49 or #50 or #51 or<br>#52 or #53 or #54 or<br>#55)<br>57. (#56 and #46) |
| <b>Donepezil</b> | 1. donepezil*<br>2. aricept*<br>3. eranz*.ti,ab.<br>4. E2020*<br>5. E?2020*<br>6. memac*<br>7. (8SSC91326P or<br>"120014 06 4" or "601<br>651 9").rn.<br>8. or/1-7<br>9. exp clinical trial/ | 1. exp Donepezil/<br>2. donepezil*<br>3. aricept*<br>4. eranz*.ti,ab.<br>5. E2020*<br>6. E?2020*<br>7. memac*<br>8. (8SSC91326P or<br>120014-06-4 or 601-<br>651-9).rn.<br>9. or/1-8 | 1. MeSH descriptor:<br>[Schizophrenia] this<br>term only<br>2. MeSH descriptor:<br>[Paranoid Disorders]<br>this term only<br>3. schizo* in Trials<br>4. hebephreni* in<br>Trials<br>5. oligophreni* in<br>Trials                                                                                       |

|                                                                               |                                                                              |                                                           |
|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------|
| 10. exp randomized controlled trials/                                         | 10. (clin\$ adj2 trial).mp.                                                  | 6. psychotic* in Trials                                   |
| 11. exp double-blind method/                                                  | 11. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).mp. | 7. psychosis in Trials                                    |
| 12. exp single-blind method/                                                  | 12. (random\$ adj5 (assign\$ or allocat\$)).mp.                              | 8. psychoses in Trials                                    |
| 13. exp cross-over studies/                                                   | 13. randomi\$.mp.                                                            | 9. chronic* in Trials                                     |
| 14. randomized controlled trial.pt.                                           | 14. crossover.mp.                                                            | 10. sever* in Trials                                      |
| 15. clinical trial.pt.                                                        | 15. exp randomized-controlled-trial/                                         | 11. mental* in Trials                                     |
| 16. controlled clinical trial.pt.                                             | 16. exp double-blind-procedure/                                              | 12. ill* in Trials                                        |
| 17. (clinic\$ adj2 trial).mp.                                                 | 17. exp crossover-procedure/                                                 | 13. disorder* in Trials                                   |
| 18. (random\$ adj5 control\$ adj5 trial\$).mp.                                | 18. exp single-blind-procedure/                                              | 14. (#9 or #10)                                           |
| 19. (crossover or cross-over).mp.                                             | 19. exp randomization/                                                       | 15. (#14 and #11)                                         |
| 20. ((singl\$ or double\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).mp. | 20. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19                 | 16. (#12 or #13)                                          |
| 21. randomi\$.mp.                                                             | 21. (schizo\$ or psychotic\$ or psychosis or psychoses).mp.                  | 17. (#15 and #16)                                         |
| 22. (random\$ adj5 (assign\$ or allocat\$ or                                  |                                                                              | 18. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #17) |
|                                                                               |                                                                              | 19. tardiv* in Trials                                     |
|                                                                               |                                                                              | 20. dyskine* in Trials                                    |
|                                                                               |                                                                              | 21. (#19 and #20)                                         |
|                                                                               |                                                                              | 22. akathisi* in Trials                                   |
|                                                                               |                                                                              | 23. acathisi* in Trials                                   |
|                                                                               |                                                                              | 24. neuroleptic* in Trials                                |
|                                                                               |                                                                              | 25. malignant in Trials                                   |
|                                                                               |                                                                              | 26. syndrome in Trials                                    |
|                                                                               |                                                                              | 27. (#25 and #26)                                         |
|                                                                               |                                                                              | 28. (#24 and #27)                                         |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>assort\$ or<br/>reciev\$)).mp.</p> <p>23. or/9-22</p> <p>24. exp<br/>SCHIZOPHRENIA/<br/>25. exp Paranoid<br/>Disorders/<br/>26. schizo\$.mp.<br/>27. hebephreni\$.mp.<br/>28. oligophreni\$.mp.<br/>29. psychotic\$.mp.<br/>30. psychosis.mp.<br/>31. psychoses.mp.<br/>32. ((chronic\$ or<br/>sever\$) adj2 mental\$<br/>adj2 (ill\$ or<br/>disorder\$)).mp.<br/>33. exp dyskinesia,<br/>drug-induced/<br/>34. exp psychomotor<br/>agitation/<br/>35. exp neuroleptic<br/>malignant syndrome/<br/>36. exp "diagnosis,<br/>dual (psychiatry)"/<br/>37. (tardiv\$ adj<br/>dyskine\$).mp.</p> | <p>22. ((chronic\$ or<br/>severe\$ or<br/>persistent\$) adj<br/>(mental\$ or<br/>psychological\$) adj<br/>(disorder\$ or ill\$)).mp.<br/>23. exp schizophrenia/<br/>24. exp psychosis/<br/>25. mental patient/<br/>26. (tardiv\$ adj<br/>dyskine\$).mp.<br/>27. neuroleptic agent/<br/>28. (neuroleptic\$ and<br/>(malignant adj2<br/>syndrome)).mp.<br/>29. tardive dyskinesia/<br/>30. akathisia/<br/>31. exp neuroleptic<br/>malignant syndrome/<br/>32. (neuroleptic\$ and<br/>movement and<br/>disorder\$).mp.<br/>33. parkinsoni\$.mp.<br/>34. parkinson's.mp.<br/>35. 21 or 22 or 23 or<br/>24 or 25 or 26 or 27 or</p> | <p>29. movement in<br/>Trials</p> <p>30. disorder* in Trials</p> <p>31. (#24 and #29 and<br/>#30)</p> <p>32. parkinsoni* in<br/>Trials</p> <p>33. neuroleptic-induc*<br/>in Trials</p> <p>34. parkinson's in<br/>Trials</p> <p>35. disease in Trials</p> <p>36. disease:ti in Trials</p> <p>37. (#34 and #36)</p> <p>38. (#21 or #22 or<br/>#23 or #28 or #31 or<br/>#32 or #33)</p> <p>39. (#38 and not #37)</p> <p>40. MeSH descriptor:<br/>[Dyskinesia, Drug-<br/>Induced] this term<br/>only</p> <p>41. MeSH descriptor:<br/>[Akathisia, Drug-<br/>Induced] explode all<br/>trees</p> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                     |                                                                                                                                                                                                                                                                                                                                                          |                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     | 38. akathisi\$.mp.<br>39. acathisi\$.mp.<br>40. (neuroleptic\$ and<br>(malignant adj2<br>syndrome)).mp.<br>41. (neuroleptic\$ and<br>(movement and<br>disorder\$)).mp.<br>42. parkinsoni\$.mp.<br>43. neuroleptic-<br>induc\$.mp.<br>44. or/37-43<br>45. 44 not (parkinson's<br>adj1 disease).ti.<br>46. or/24-36<br>47. 45 or 46<br>48. 8 and 23 and 47 | 28 or 29 or 30 or 31 or<br>32 or 33 or 34<br>36. 35 not<br>parkinson's.ti.<br>37. 20 and 36<br>38. 9 and 37 | 42. MeSH descriptor:<br>[Neuroleptic<br>Malignant Syndrome]<br>this term only<br>43. (#39 or #40 or<br>#41 or #42)<br>44. (#43 or #18)<br>45. MeSH descriptor:<br>[Schizophrenia<br>Spectrum and Other<br>Psychotic Disorders]<br>this term only<br>46. (#45 or #44)<br>47. donepezil*<br>48. aricept*<br>49. eranz*:ti,ab<br>50. E2020*<br>51. E?2020*<br>52. 8SSC91326P<br>53. (#47 or #48 or<br>#49 or #50 or #51 or<br>#52)<br>54. (#53 and #46) |
| <b>Rivastigmine</b> | 1. exp rivastigmine/<br>2. rivastigmin*<br>3. exelon*.ti,ab.<br>4. Nimvastid.ti,ab.                                                                                                                                                                                                                                                                      | 1. exp rivastigmine/<br>2. rivastigmin*<br>3. exelon*.ti,ab.<br>4. Nimvastid.ti,ab.                         | 1. MeSH descriptor:<br>[Schizophrenia] this<br>term only                                                                                                                                                                                                                                                                                                                                                                                             |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5. Nimvastid<br>6. (PKI06M3IW0 or "123441 03 2" or "602 936 0").rn.<br>7. ENA?713*<br>8. or/1-7<br>9. exp<br>SCHIZOPHRENIA/<br>10. exp Paranoid Disorders/<br>11. schizo\$.mp.<br>12. hebephreni\$.mp.<br>13. oligophreni\$.mp.<br>14. psychotic\$.mp.<br>15. psychosis.mp.<br>16. psychoses.mp.<br>17. ((chronic\$ or sever\$) adj2 mental\$ adj2 (ill\$ or disorder\$)).mp.<br>18. exp dyskinesia, drug-induced/<br>19. exp psychomotor agitation/<br>20. exp neuroleptic malignant syndrome/ | 5. Nimvastid<br>6. (PKI06M3IW0 or "123441 03 2" or "602 936 0").rn.<br>7. ENA?713*<br>8. or/1-7<br>9. (schizo\$ or psychotic\$ or psychosis or psychoses).mp.<br>10. ((chronic\$ or severe\$ or persistent\$) adj (mental\$ or psychological\$) adj (disorder\$ or ill\$)).mp.<br>11. exp schizophrenia/<br>12. exp psychosis/<br>13. mental patient/<br>14. (tardiv\$ adj dyskine\$).mp.<br>15. neuroleptic agent/<br>16. (neuroleptic\$ and (malignant adj2 syndrome)).mp.<br>17. tardive dyskinesia/<br>18. akathisia/ | 2. MeSH descriptor: [Paranoid Disorders] this term only<br>3. schizo* in Trials<br>4. hebephreni* in Trials<br>5. oligophreni* in Trials<br>6. psychotic* in Trials<br>7. psychosis in Trials<br>8. psychoses in Trials<br>9. chronic* in Trials<br>10. sever* in Trials<br>11. mental* in Trials<br>12. ill* in Trials<br>13. disorder* in Trials<br>14. (#9 or #10)<br>15. (#14 and #11)<br>16. (#12 or #13)<br>17. (#15 and #16)<br>18. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #17)<br>19. tardiv* in Trials<br>20. dyskine* in Trials<br>21. (#19 and #20)<br>22. akathisi* in Trials |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 21. exp "diagnosis,<br>dual (psychiatry)"/<br>22. (tardiv\$ adj<br>dyskine\$).mp.<br>23. akathisi\$.mp.<br>24. acathisi\$.mp.<br>25. (neuroleptic\$ and<br>(malignant adj2<br>syndrome)).mp.<br>26. (neuroleptic\$ and<br>(movement and<br>disorder\$)).mp.<br>27. parkinsoni\$.mp.<br>28. neuroleptic-<br>induc\$.mp.<br>29. or/22-28<br>30. 29 not (parkinson's<br>adj1 disease).ti.<br>31. or/9-21<br>32. 30 or 31<br>33. exp clinical trial/<br>34. exp randomized<br>controlled trials/<br>35. exp double-blind<br>method/<br>36. exp single-blind<br>method/ | 19. exp neuroleptic<br>malignant syndrome/<br>20. (neuroleptic\$ and<br>movement and<br>disorder\$).mp.<br>21. parkinsoni\$.mp.<br>22. parkinson's.mp.<br>23. 9 or 10 or 11 or 12<br>or 13 or 14 or 15 or 16<br>or 17 or 18 or 19 or 20<br>or 21 or 22<br>24. 23 not<br>parkinson's.ti.<br>25. (clin\$ adj2<br>trial).mp.<br>26. ((singl\$ or doubl\$<br>or trebl\$ or tripl\$) adj<br>(blind\$ or mask\$)).mp.<br>27. (random\$ adj5<br>(assign\$ or<br>allocat\$)).mp.<br>28. randomi\$.mp.<br>29. crossover.mp.<br>30. exp randomized-<br>controlled-trial/<br>31. exp double-blind-<br>procedure/ | 23. acathisi* in Trials<br>24. neuroleptic* in<br>Trials<br>25. malignant in Trials<br>26. syndrome in<br>Trials<br>27. (#25 and #26)<br>28. (#24 and #27)<br>29. movement in<br>Trials<br>30. disorder* in Trials<br>31. (#24 and #29 and<br>#30)<br>32. parkinsoni* in<br>Trials<br>33. neuroleptic-induc*<br>in Trials<br>34. parkinson's in<br>Trials<br>35. disease in Trials<br>36. disease:ti in Trials<br>37. (#34 and #36)<br>38. (#21 or #22 or<br>#23 or #28 or #31 or<br>#32 or #33)<br>39. (#38 and not #37) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                               |                                                              |                                                                                            |
|-------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| 37. exp cross-over studies/                                                   | 32. exp crossover-procedure/                                 | 40. MeSH descriptor: [Dyskinesia, Drug-Induced] this term only                             |
| 38. randomized controlled trial.pt.                                           | 33. exp single-blind-procedure/                              | 41. MeSH descriptor: [Akathisia, Drug-Induced] explode all trees                           |
| 39. clinical trial.pt.                                                        | 34. exp randomization/                                       | 42. MeSH descriptor: [Neuroleptic Malignant Syndrome] this term only                       |
| 40. controlled clinical trial.pt.                                             | 35. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 | 43. (#39 or #40 or #41 or #42)                                                             |
| 41. (clinic\$ adj2 trial).mp.                                                 | 36. 8 and 24 and 35                                          | 44. (#43 or #18)                                                                           |
| 42. (random\$ adj5 control\$ adj5 trial\$).mp.                                |                                                              | 45. MeSH descriptor: [Schizophrenia Spectrum and Other Psychotic Disorders] this term only |
| 43. (crossover or cross-over).mp.                                             |                                                              | 46. (#45 or #44)                                                                           |
| 44. ((singl\$ or double\$ or trebl\$ or tripl\$) adj (blind\$ or mask\$)).mp. |                                                              | 47. MeSH descriptor: [Rivastigmine] explode all trees                                      |
| 45. randomi\$.mp.                                                             |                                                              | 48. rivastigmin*                                                                           |
| 46. (random\$ adj5 (assign\$ or allocat\$ or assort\$ or reciev\$)).mp.       |                                                              | 49. exelon*:ti,ab                                                                          |
| 47. or/33-46                                                                  |                                                              | 50. Nimvastid:ti,ab                                                                        |
| 48. 8 and 32 and 47                                                           |                                                              |                                                                                            |

|  |  |  |                                                                                                          |
|--|--|--|----------------------------------------------------------------------------------------------------------|
|  |  |  | 51. Nimvastid<br>52. ENA?713*<br>53. (#47 or #48 or<br>#49 or #50 or #51 or<br>#52)<br>54. (#53 and #46) |
|--|--|--|----------------------------------------------------------------------------------------------------------|

## **Appendix 2. Excluded studies.**

### ***Aasen 2005***

Aasen I, Kumari V, Sharma T. Effects of rivastigmine on sustained attention in schizophrenia. An fMRI study. Journal of Clinical Psychopharmacology 2005;25(4):311-7. [Wrong outcomes: the study does not report cognitive outcomes].

### ***Buchanan 2017***

Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT. A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia. Journal of Clinical Psychopharmacology 2017;37(4):394-400. [Wrong intervention: intranasal oxytocin plus galantamine].

### ***Chouinard 2007***

Chouinard S, Stip E, Poulin J, Melun JP, Godbout R, Guillem F, Cohen H. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Current Medical Research and Opinion 2007;23(3):575-83. [Data presentation do not allow the extraction of effect sizes for cognitive outcomes].

### ***Conley 2009***

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball P, Buchanan RW. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clinical Neuropharmacology 2009;32(2):69-74. [Wrong outcomes: The study does not report cognitive outcomes].

### ***Deutsch 2013***

Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophrenia Research 2013;148:138-44. [Wrong intervention: alpha-7 nicotinic agonist].

***Erickson 2005***

Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. *Clinical Neuropharmacology* 2005;28(4):179-84. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Fagerlund 2007***

Fagerlund B, Sørholm B, Fink-Jensen A, Lublin H, Glenthøj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. *Clinical Neuropharmacology* 2007;30(1):3-12. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Freedman 2008***

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J. Initial phase 2 trial of a nicotinic agonist in schizophrenia. *American Journal of Psychiatry* 2008;165:1040-7. [Wrong intervention: alpha-7 nicotinic agonists].

***Friedman 2002***

Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. *Biological Psychiatry* 2002;51:349-57. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Goff 2008***

Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. *Neuropsychopharmacology* 2008;33:465-72. [Wrong intervention: AMPA-receptor-positive modulator].

***Guillem 2006***

Guillem F, Chouinard S, Poulin J, Godbout R, Lalonde P, Melun P, Bentaleb LA, Stip E. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2006;30:934-45. [Wrong outcomes: the study does not report cognitive outcomes].

***Hashimoto 2009***

Hashimoto K. Nausea associated with nicotinic agonist therapy in schizophrenia. *Clinical Psychopharmacology and Neuroscience* 2009;7(1):26-7. [Wrong intervention: alpha-7 nicotinic agonist].

***Keefe 2008***

Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. *Neuropsychopharmacology* 2008;33:1217-28. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Kelly 2008***

Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR, Buchanan RW. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. *Schizophrenia Research* 2008;103:161-8. [Wrong outcomes: the study does not present cognitive outcomes]. [Wrong outcomes: the study does not report cognitive outcomes].

***Kohler 2007***

Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.

Cognitive Neuropsychiatry 2007;12(5):412-21. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Kumari 2006***

Kumari V, Aasen I, Ffytche D, Williams SCR, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. NeuroImage 2006;29:545-56. [Wrong outcomes: the study does not report cognitive outcomes].

***Lieberman 2009***

Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009;34:1322-9. [Wrong intervention: memantine, a NMDA receptor antagonist].

***Lindenmayer 2011***

Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophrenia Research 2011;125:267-77. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Matthews 2013***

Matthews JD, Siefert CJ, Blais MA, Park LT, Welch CA, DuBois CM, van Nieuwenhuizen AO, Rooney KO, Seabrook RC, Durham LE, Adams HC, Fava M. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. Journal of ECT 2013;29(3):170-8. [Wrong intervention: galantamine during electroconvulsive therapy].

***Mazeh 2006***

Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-

controlled study. International Psychogeriatrics 2006;18(3):429-36. [Wrong outcomes: outcome data do not fit cognitive domains].

#### ***Morozova 2014***

Morozova MA, Lepilkina TA, Rupchev GE, Beniashvily AG, Burminskiy DS, Potanin SS, Bondarenko EV, Kazey VI, Lavrovsky Y, Ivachtchenko AV. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectrums 2014;19(4):316-23. [Wrong intervention: 5HT6 receptors selective agonist].

#### ***Muscatello 2011***

Muscatello MRA, Bruno A, Pandolfo G, Micò U, Bellinghieri PM, Scimeca G, Cacciola M, Campolo D, Settineri S, Zoccali R. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Journal of Psychopharmacology 2011;25(5):667-74. [Wrong intervention: topiramate, an antiepileptic drug].

#### ***Nahas 2003***

Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, Owens SD, McGurk S, DeVane L, Risch SC. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 2003;9(3):274-82. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

#### ***Olincy 2006***

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial of an  $\alpha 7$  nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006;63:630-8. [Wrong intervention: alpha-7 nicotinic agonist].

#### ***Pérez 2006***

Pérez M, Tůma I, Pytela O, Kadleecová E, Zemanová M, Lenderová Z.

Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study. *European Psychiatry* 2006;21:548-50. [Wrong comparison: subanalysis of a single pre-post within group].

#### ***Risch 2001***

Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. *Neurocase* 2001;7:105-10. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

#### ***Risch 2006***

Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL. Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. *International Journal of Neuropsychopharmacology* 2006;9:603-5. [Wrong outcomes: the study does not report cognitive outcomes].

#### ***Risch 2007***

Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. *Schizophrenia Research* 2007;93:131-5. [Wrong outcomes: the study does not report cognitive outcomes].

#### ***Sacco 2008***

Sacco KA, Creeden C, Reutenauer EL, George TP. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. *Schizophrenia Research* 2008;103:326-7. [Wrong comparison: smokers versus non smokers].

#### ***Schubert 2006***

Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. *Biological Psychiatry* 2006;60:530-33. [Wrong outcomes: the outcome data do not fit cognitive domains].

***Shafti 2016***

Shafti SS, Khoei AA. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. *Therapeutic Advances in Psychopharmacology* 2016;6(5):308-16. [Wrong outcomes: the study does not report cognitive outcomes].

***Sharma 2006***

Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. *Schizophrenia Research* 2006;85:73-83. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Stryjer 2004***

Stryjer R, Strous R, Bar F, Shaked G, Shiloh R, Rozenzweig S, Grupper D, Buchman N, Kotler M, Rabey JM, Weizman A. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. *Human Psychopharmacology* 2004;19:343-6. [Data presentation does not allow the extraction of effect sizes for cognitive outcomes].

***Stryjer 2012***

Stryjer R, Ophir D, Bar F, Spivak B, Weizman A, Strous RD. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. *Clinical Neuropharmacology* 2012;35(4):161-4. [Wrong outcomes: the outcome data do not fit cognitive domains].

***Tregellas 2010***

Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. *Neuropsychopharmacology* 2010;35:938-42. [Wrong intervention: alpha-7 nicotinic agonist].

***Tregellas 2011***

Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. *Biological Psychiatry* 2011;69:7-11. [Wrong intervention: alpha-7 nicotinic agonist].

***Velligan 2012***

Velligan D, Brenner R, Sicuro F, Walling D, Riesenberger R, Sfera A, Merideth C, Sweitzer D, Jaeger J. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. *Schizophrenia Research* 2012;134:59-64. [Wrong intervention: alpha-4beta-2 nicotinic agonist].